2022年度肺癌领域重要临床研究进展  

Important clinical research progress in lung cancer in 2022

作　　者：苏春霞[1] 周彩存[1] SU Chunxia;ZHOU Caicun(Department of Medical Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《中国癌症杂志》2023年第3期218-227,共10页China Oncology

基　　金：国家自然科学基金面上项目(82072568)

摘　　要：肺癌仍然是中国发病率和死亡人数最高的恶性肿瘤,其中,非小细胞肺癌(non-small cell lung cancer,NSCLC)约占80%以上。围手术期NSCLC辅助免疫治疗和新辅助免疫治疗相关临床研究推陈出新。靶向治疗方面,罕见及难治性肺癌靶点探索和药物研发持续推进,抗体药物偶联物的研发方兴未艾,有望开辟肺癌诊疗新途径。NSCLC诊疗逐渐步入精准化、规范化时代。在晚期NSCLC患者免疫治疗方面,免疫联合新方案有望进一步提高疗效。本文回顾2022年度NSCLC治疗领域的临床进展,阐述现阶段面临的问题和挑战,并探讨未来发展方向。Lung cancer remains the malignant tumor with the highest morbidity and mortality in China,among which nonsmall cell lung cancer(NSCLC)accounts for more than 80%.Clinical studies related to adjuvant immunotherapy and neoadjuvant immunotherapy in perioperative NSCLC have been updated.In terms of targeted therapy,the research and development of drugs for rare and difficult-to-treat targets continues to be hot,and the research and development of antibody-drug conjugate gradually becomes hot,which is expected to open a new track for the diagnosis and treatment of lung cancer.Rare target diagnosis and treatment of NSCLC has gradually entered an era of precision and standardization.In terms of immunotherapy for patients with advanced NSCLC,the new regimen of combined immunotherapy is expected to further improve the efficacy.This review,with the focus on advanced NSCLC,summarized the development of NSCLC,discussed current problems and challenges,and proposed prospects on future directions.

关 键 词：非小细胞肺癌 围手术期 靶向治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]